AbCellera

TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company employs its proprietary TetraExpress system to produce recombinant human ion channel proteins, which are essential for creating complex therapeutic agents. Among its offerings is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. TetraGenetics specializes in producing difficult-to-express eukaryotic membrane and secretory proteins, including vaccine antigens and monoclonal antibodies, which are crucial for treating various human and animal diseases. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., further enhancing its capabilities in therapeutic innovation.

Trianni, Inc. is a biotechnology company based in San Francisco, California, founded in 2010. It specializes in developing a humanized monoclonal antibody platform, which includes The Trianni Mouse, an advanced antibody discovery platform. This platform enables researchers to access a human antibody repertoire, facilitating the efficient isolation of monoclonal antibodies. Trianni's technology aims to enhance immune responses, increase antibody diversity, and maintain the natural maturation of fully human antibodies in rodents. By providing these innovative solutions, Trianni seeks to improve the speed and success rates of antibody-drug development for preventing and treating various diseases.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies. The company specializes in producing antibodies using standard production and purification techniques which are available in flexible formats that can be tailored to specific target biology and mechanisms of action.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Lineage Biosciences is a biotechnology company that specialises in deep analysis of anti-body responses of human body.